Ticagrelor Administered as Standard Tablet or orodispersiblE foRmulation
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 130
- Locations
- 1
- Primary Endpoint
- Evaluation of Platelet Inhibition
Study Overview
Brief Summary
Randomized clinical study evaluating superiority in platelet inhibition after administration of Ticagrelor 180 mg loading dose as an orodispersible formulation versus traditional coated tablets in patients admitted for ST elevation myocardial infarction or very high-risk non-ST elevation myocardial infarction.
Detailed Description
Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for patients with acute ST-segment elevation myocardial infarction (STEMI). Additional antithrombotic therapy prior or during intervention plays an important role in the short- and long-term outcomes after PPCI. Oral antiplatelet therapy including a platelet P2Y12 receptor inhibitors is a cornerstone of antithrombotic treatment in patients with acute coronary syndromes. Prasugrel and Ticagrelor have been shown to be superior to Clopidogrel in patients with STEMI in reduction of ischemic complication without any increase in the bleeding risk and with a significant reduction in the stent thrombosis rate. Nevertheless, in STEMI patients, pharmacodynamic studies showed prasugrel and ticagrelor oral loading dose (LD) provided a suboptimal platelet inhibition in the first hours after LD, and at least 4 hours are required to achieve and effective platelet aggregation inhibition in the majority of patients, in part due to slowed gut motility caused by morphine use. Orodispersible tablet (ODT) is a different tablet formulation that disperses upon contact with the moist mucosal surfaces of the oral cavity and quickly release its components before swallowing; thus local drug dissolution and absorption as well as onset of clinical effect can be obtained conveniently easily and quickly by bypassing gastrointestinal tract. Recently, Ticagrelor 90 mg ODT has become available and bioequivalence studies on healthy volunteers documented its effectiveness with consequent approval by European Medicine Agency of this formulation which is currently available on the market. Thus, the aim of the present study is to evaluate the superiority in platelet inhibition with 180 mg Ticagrelor loading dose (LD) administered as ODTs as compared with standard formulation, among patients with STEMI or very high-risk NSTEMI undergoing immediate PCI. Primary objective consists in evaluating platelet reactivity 1 hour after Ticagrelor loading dose by VerifyNow test.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Investigator)
Masking Description
Site investigators performing platelet function tests will be blinded regarding patient randomization arm and the blood samples will be fully anonymized.
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients presenting within 12 hours from the onset of symptoms with STEMI or very high-risk NSTEMI referred for immediate (< 2 hours) angiography. Very high-risk NSTEMI patients include patients with haemodynamic instability or cardiogenic shock, heart failure, life-threatening arrhythmias or resuscitated cardiac arrest, intermittent ST-segment elevation, or ongoing chest pain.
- •Informed, written consent
- •Male or female patients, aged ≥ 18 years old
Exclusion Criteria
- •Age < 18 years
- •Active bleeding; bleeding diathesis; coagulopathy
- •History of gastrointestinal or genitourinary bleeding <2 months
- •Major surgery in the last 6 weeks
- •History of intracranial bleeding or structural abnormalities
- •Suspected aortic dissection
- •Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux.
- •Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers, CYP3A with narrow therapeutic window
- •Known relevant hematological deviations: Hb <10 g/dl, Thromb. <100x10^9/l
- •Use of warfarin or new oral anticoagulant derivatives within the last 7 days
- •Known severe liver disease, severe renal failure
- •Allergy or hypersensitivity to ticagrelor or any of the excipients.
- •Pregnancy or lactation
Arms & Interventions
Ticagrelor standard tablets
STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as standard coated tablets.
Intervention: administration of Ticagrelor 180 mg loading dose as standard coated pills.
Intervention: Ticagrelor standard tablets (Drug)
Ticagrelor orodispersible tablets
STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as orodispersible tablets.
Intervention: administration of Ticagrelor 180 mg loading dose as orodispersible tablets.
Intervention: Ticagrelor orodispersible tablets (Drug)
Outcomes
Primary Outcomes
Evaluation of Platelet Inhibition
Time Frame: 1 hour
Platelet reactivity will be measured by VerifyNow test 1 hour after Ticagrelor loading dose (LD) administered as orodispersible tablets as compared with standard formulation in 130 patients with STEMI or very high-risk NSTEMI undergoing immediate PCI. The VerifyNow PRU Test is designed to measure P2Y12 receptor blockade. Results of the PRU Tests are reported as P2Y12 Reaction Units (PRU). PRU measures the extent of platelet aggregation in the presence of a P2Y12 inhibitor. Lower PRU levels are associated with expected antiplatelet effect.
Secondary Outcomes
- Number of Participants With Clinically Relevant Bleeding Events(30 days)
- Percent of Patients With Insufficient Antiaggregation(1 hour)
- Number of Participants With Residual Platelet Reactivity at Various Timepoints(2, 4 and 6 hours)
Investigators
Prof. Guido Parodi
Professor
Azienda Ospedaliero Universitaria di Sassari